BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Priothera SAS readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Priothera SAS's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05429632-2980@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:mocravimod: Phase 3 readout est. (NCT05429632)
DESCRIPTION:mocravimod\, phase 3\, Acute Myeloid Leukemia.\nStudy: Mocravim
 od as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo
 -HCT\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mocravimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05429632
URL:https://assetmemo.bio/drug/mocravimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
